Resources

This brief summarizes key findings from a literature review conducted by PATH to identify published and gray literature reporting international experiences with the Uniject™ injection system. The findings shed light on user acceptability and highlight potential cost savings in terms of training time, waste management, and reduction in drug wastage when Uniject is used instead of a standard autodisable syringe. This document synthesizes the experience and evidence on the use of Uniject worldwide with medicines such as the injectable contraceptive Cyclofem®, hepatitis B and tetanus toxoid vaccines, as well as the drug oxytocin, which is used to prevent postpartum hemorrhage.

This brief describes results from an analysis conducted by PATH comparing the current intramuscular version of depot medroxyprogesterone acetate (DMPA) injectable contraceptive compared with a new formulation packaged in the Uniject™ injection system. The analysis focused on waste management implications, identifying key quantitative and qualitative differences between the two products.

This brief summarizes the strategic demand models developed by PATH and the Futures Institute for the injectable contraceptive depo-subQ provera 104™ in the Uniject™ injection system (depo-subQ in Uniject) in Kenya, Malawi, Pakistan, Rwanda, and Senegal. These models will help inform global and country introduction planning for depo-subQ in Uniject.

It is widely recognized today that ensuring a reliable supply of quality contraceptives is essential to reproductive health programs. The tagline "No product? No program" is known, understood, and embraced by those working to support reproductive health in the developing world. But this was not always the case. This paper tells the story of how what was once seen only as a technical issue became a global movement.

This report is part of the Cervical Cancer Prevention: Practical Experience Series on the RHO Cervical Cancer website. It aims to help decision-makers and program planners focus on key “big picture" questions about cervical cancer prioritization and on opportunities and challenges for improved cancer prevention, including vaccination of girls and precancer screening and treatment of adult women.